Assessment of Large-Sample Unit-Dose Uniformity Tests - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Assessment of Large-Sample Unit-Dose Uniformity Tests
The authors describe the concept of the limiting discriminatory threshold (LDT) as an objective means of evaluating the inherent quality requirement of a large-sample content-uniformity test.

Pharmaceutical Technology
Volume 35, Issue 10, pp. 82-92

LDT estimation for the hUSP zero-tolerance criterion

Eq. 2 is used to estimate the LDT of the nonparametric zero-tolerance (ZT) criterion in Stage 2 of the hUSP test. Assuming that a batch true mean is at the target potency of 100% LC, the ZT criterion requires all tested units to be within the range of 75–125% LC. If Q represents the true 75–125% LC coverage of the batch, the probability of acceptance (Eq. 1) is expressed in the following equation:

The above equation may be inverted to solve for Q, thus yielding the following result:

Substituting the above equation into Eq. 2 and solving for the limit yields the following result:

Thus, the hUSP ZT criterion inherently would require a 75–125% LC coverage of 100%, which, as argued above, cannot be attained with existing technologies. The ZT criterion is useful as a failsafe in the current hUSP test to protect against an accidental serious failure that is not otherwise detected because of the small sample size. However, the ZT criterion in large-sample-size UDU tests may be unnecessarily stringent and dissuade personnel from performing testing.

LDT estimation for the hUSP test without the ZT criterion

The hUSP test does not explicitly define the inherent quality requirement. Because the test only applies to a small sample size, it will exhibit nonzero Type I and Type II errors. The test effectively establishes an acceptable standard for the Type I error probability that is determined by the Stage 2 criteria. Therefore, the LDT for the hUSP test without the ZT requirement, referred to as hUSP (–ZT) can be determined solely based on the Stage 2 acceptance-value requirement. This LDT can serve as a benchmark of the quality level that is expected in production batches.

Assuming a target potency (T) of 100% LC, the Stage 2 AV requirement can be expressed by the following equation:

Figure 1 contains definitions of L, M, S, and X.

The batch means above 100% LC are the mirror images of the ones below 100%, and thus are not considered in Eq. 7. The limiting coverage at large sample size is expressed in the following equation:

Figure 3: Limiting discrimination threshold (LDT) coverage of the hUSP(-ZT) test as a function of batch means, assuming a normal population distribution and target assay of 100% label claim (LC).
in which N(x|μ,σLDT) is the normal probability density function. The LDT for a normal population distribution (Eq. 8) is shown in Figure 3 as a function of population mean.

The LDTs are 95.45% and 95.96% for batch means of 100% LC and 96% LC, respectively. The dip in LDT curve at batch mean of 98.5% LC results from the indifference zone of the hUSP test. Clearly, the most stringent coverage requirement of about 96% occurs at a batch mean near 96% LC. This requirement is more conservative than that of Sandell (i.e., 95.2%), but less conservative than that of Bergum and Vukovinsky (i.e., 97%).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here